InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: north40000 post# 198764

Sunday, 12/07/2014 8:51:57 PM

Sunday, December 07, 2014 8:51:57 PM

Post# of 346056
north40000, thanks for bringing this up with Dr. Patrick Soon-Shiong on 60 Minutes. It was all interesting, but one point I will make is that Dr. Patrick Soon-Shiong mentioned:

the problem is that certain cells are not dying

So I ask: "What exists on cells that are not dying" ... that should be death, though stick around and join the cancer cell club.

Flipped PS

Flipped PS

Flipped PS

... Seems to me that he knows quite well that flipped PS must be targeted and only one company has the patent rights to it.

Peregrine Pharmaceuticals

** No matter what any other biotech may say in how they stop it... targeting flipped PS must come first


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News